The Technical Analyst
Auris Medical Holding Ltd [EARS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Auris Medical Holding Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.77% CHF3.05
America/New_York / 26 jul 2021 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.21 mill |
| EPS: | -1.482 |
| P/E: | -2.05 |
| Earnings Date: | N/A |
| SharesOutstanding: | 1.384 mill |
| Avg Daily Volume: | 1.894 mill |
| RATING 2021-07-23 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | |||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.05 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.35x |
| Company: PE -2.05 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
CHF 2.80 - 3.29 ( +/- 7.98%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CHF3.05 (-1.77% ) |
| Volume | 0.174 mill |
| Avg. Vol. | 1.894 mill |
| % of Avg. Vol | 9.19 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EARS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EARS
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.
Latest Press Releases
2021-07-16 09:00:00 - Press Release
Auris Medical Announces Launch Of New Corporate Website
Hamilton, bermuda, july 15, 2021 – auris medical holding ltd. (nasdaq: ears), a company dedicated to addressing unmet medical needs through rna therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. the new website features a streamlined and modern design and also reflects the company's recently announced strategic repositioning.
2021-07-14 09:00:00 - Press Release
Auris Medical Announces Publication Of Data From Preclinical Studies With Bentrio™ Nasal Spray In Prevention And Mitigation Of Sars-cov-2
Hamilton, bermuda, july 14, 2021 – auris medical holding ltd. (nasdaq: ears), a company dedicated to addressing unmet medical needs through rna therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its bentrio™ (am-301) nasal spray development program in sars-cov-2. am-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. the manuscript describing these preclinical data is available on a preprint server at https://www.biorxiv.org/content/10.1101/2021.07.12.452021v1 and will undergo scientific peer-review for potential publication.
2021-06-28 08:30:00 - Press Release
Auris Medical To Initiate Market Launch Of Bentrio™ Nasal Spray In Germany
Hamilton, bermuda, june 28, 2021 – auris medical holding ltd. (nasdaq: ears), a company dedicated to addressing unmet medical needs through rna therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate altamira medica ltd. will start the market roll-out of bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in germany. bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries.
2021-05-28 08:30:00 - Press Release
Auris Medical Holding To Present At Ld Micro Invitational Xi Conference
Hamilton, bermuda, may 28, 2021 – auris medical holding ltd. (nasdaq: ears), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and cns disorders, today announced that chairman and ceo thomas meyer will present at the ld micro invitational xi investor conference on wednesday june 9, 2021, at 11:00 a.m. est (track 2). the event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.
2021-05-14 08:30:00 - Press Release
Auris Medical Reaches Midpoint For Enrollment In Part B Of Am-125 Phase 2 Travers Trial In Acute Peripheral Vertigo
Hamilton, bermuda, may 14, 2021 – auris medical holding ltd. (nasdaq: ears), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and cns disorders, today announced that it has reached the midpoint for enrollment in part b of its phase 2 proof-of-concept trial of am-125 (intranasal betahistine) in the treatment of acute peripheral vertigo.
Latest News
2021-07-16 09:00:00 - GlobeNewsWire
Auris Medical Announces Launch of New Corporate Website
Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company's recently announced strategic repositioning.
2021-07-14 15:58:58 - PennyStocks
5 Reddit Penny Stocks to Watch That Are Moving Right Now
Are these Reddit penny stocks worth adding to your small-caps watchlist right now? The post 5 Reddit Penny Stocks to Watch That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-07-14 11:40:30 - Benzinga
Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19
Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional preclinical data in a primary human nasal airway epithelium model from its Bentrio (AM-301) nasal spray for COVID-19. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.
2021-07-14 09:00:00 - GlobeNewsWire
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript describing these preclinical data is available on a preprint server at https://www.biorxiv.org/content/10.1101/2021.07.12.452021v1 and will undergo scientific peer-review for potential publication.
2021-06-28 08:30:00 - GlobeNewsWire
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries.
2021-06-21 09:28:07 - Pulse2
EARS Stock Price Increases Over 14% Pre-Market
The stock price of Auris Medical Holding Ltd. (NASDAQ: EARS) increased by over 14% pre-market.
2021-06-03 09:17:12 - Benzinga
Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs
Auris Medical Holding Ltd (NASDAQ: EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77 million common shares, the assumption of certain selling shareholders' cash outlays, as well as a future share-based payment contingent on reaching a specific development milestone.
2021-06-03 08:51:26 - Pulse2
EARS Stock Price: Over 9% Increase Pre-Market Explanation
The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) increased by over 9% pre-market. This is why it happened.
2021-05-28 08:30:00 - GlobeNewsWire
Auris Medical Holding to Present at LD Micro Invitational XI Conference
Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.
2021-05-14 08:30:00 - GlobeNewsWire
Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo
Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it has reached the midpoint for enrollment in Part B of its Phase 2 proof-of-concept trial of AM-125 (intranasal betahistine) in the treatment of acute peripheral vertigo.